Le médicament du mois. L'étanercept (Enbrel) pour le traitement du psoriasis en plaques modéré a sévère.

Clinical Trials as Topic; Humans; Immunoglobulin G/therapeutic use; Immunosuppressive Agents/therapeutic use; Psoriasis/drug therapy; Receptors, Tumor Necrosis Factor/therapeutic use; Severity of Illness Index

Abstract :

[en] Etanercept (Enbrel) is a soluble tumour necrosis factor (TNF) receptor drug. By this mechanism, it inhibits the effects of TNF-alpha involved in the pathogenesis of psoriasis. Enbrel is approved for the treatment of moderate to severe chronic plaque psoriasis, and also for psoriatic arthritis.

Disciplines :

Dermatology

Author, co-author :

Franchimont, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

French

Title :

Le médicament du mois. L'étanercept (Enbrel) pour le traitement du psoriasis en plaques modéré a sévère.

Alternative titles :

[en] Etanercept (Enbrel) for the treatment of moderate to severe plaque type psoriasis.

Publication date :

2006

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

201-5

Peer reviewed :

Peer reviewed

Available on ORBi :

since 11 February 2009

Statistics

Number of views

278 (7 by ULiège)

Number of downloads

259 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Jablonska S, Majewski S.- On the immunopathogenesis of psoriasis. Arch Dermatol, 2001, 137, 229-230.
Krueger JG.- The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2003, 49, S118-S124.
Piérard GE, Piérard-Franchimont C.- Formation de l'hyperplasie dermo-épidermique dans le psoriasis. Ann Dermatol Venereal, 1983, 110, 891-897.
Uhoda I, Piérard-Franchimont C, Piérard GE, et al.-Vascularity and fractal dimensions of the dermo-epidermal interface in guttate and plaque type psoriasis. Dermatology, 2005, 210, 189-193.
Kupper TS.- Immunologie targets in psoriasis. N Engl J Med, 2003, 349, 1987-1990.
Mussi A, Bonifati C, Carducci M, et al.- Serum TNF-α levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Ag, 1997, 11, 115-118.
Bonifati C, Carducci M, Cordiali Fei P, et al.- Correlated increases of tumour necrosis factor-a, interleukin-6 and granulocytes monocytes-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients. Relationships with disease severity. Clin Exp Dermatol, 1994, 19, 383-387.
Ameglio F, Bonifati C, Pietravalle M, et al.- Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology, 1994, 189, 359-363.
Kirby B, Griffiths CEM.- Novel immune-based therapies for psoriasis. Br J Dermatol, 2002, 146, 546-551.
Singri P, West DP, Gordon KB.- Biologic therapy for psoriasis. Arch Dermatol, 2002, 183, 657-663.
FDA Safety update on TNF-α antagonists: infliximab and etanercept, 2001.
US Food and Drug Adminisration Web Site. Enbrel (etanercept) package insert. Seattle, WA: immunex Corp; 2004. www.fda.gov/cder/foi/label/2002/Eta- nimm091202LB.pdf (consulté le 2.11.05)
Mease PJ, Goffe BS, Metz J, et al.- Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet, 2000, 356, 385-390.
Gottlieb AB, Matheson RT, Lowe N, et al.- A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol, 2003, 139, 1627-1632
Leonardi CL, Powers JL, Matheson RT, et al.- Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 2003, 349, 2014-2022.
Dadlani C, Orlow SJ.- Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologie and rheumatologic literature. J Am Acad Dermatol, 2005, 52, 316-340.
Papp KA, Tyring S, Lahfa M, et al.- A global phase III randomized controled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol, 2005, 152, 1304-1312.
Lebwohl M.- Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol, 2003, 49, S118-S24.
Fredriksson T, Pettersson U.- Severe psoriasis-oral therapy with a new retinoid. Dermatologica, 1978, 157, 238-244.
Feldman SR.- A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat, 2004, 15, 27-29.
Mohan N, Edwards ET, Cupps TR, et al.- Demyelination occurring during anti-tumor necrosis factor-alpha therapy for inflammatory arthritides. Arthritis Rheum, 2001, 44, 862-2869.
Robinson WH, Genovese MC, Moreland LW.- Demyelinating and neurologic events reported in association with tumor necrosis factor-α antagonism. Arthritis Rheum, 2001, 44, 1977-1983.
Brown SL, Greene MH, Gershon SK, et al.- Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum, 2002, 46, 3151-3158.
Criscione LG, St Clari EW.- Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Curr Opin Rheum, 2002, 14, 204-211.
Lee JH, Slifman NR, Gershon SK, et al.- Life threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept. Arthritis Rheum, 2002, 46, 2565-2570.
Ellerin T, Rubin RH, Weinblatt ME.- Infections and anti-tumor necrosis factor Atherapy. Arthritis Rheum, 2003, 48, 3013-3022.
Gardam MA, Keystone EC, Menzies R, et al.- Antitumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis, 2003, 3, 148-155.
Khanna M, Shirodkar MA, Gottlieb AB.- Etanercept therapy in patients with autoimmunity and hepatitis C. J Dermatol Treat, 2003, 14, 229-232.
Kavanaugh A, Keystone EC.- The safety of biologic agents in early rheumatoid arthritis. Clin Exp Rheum, 2003, 21, S203-S208.
Elkayam O, Caspi D, Reitblatt T, et al.- The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum, 2004, 33, 283-288.
Manadan AM, Mohan AK, Cote TR, et al.- Tuberculosis and etanercept treatment. Arthritis Rheum, 2004, 46, S166.
Wallis RS, Broder MS, Wong JY, et al.- Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis, 2004, 38, 1261-1265.
Thielen AM, Kuenzli S, Saurat JH.- Cutaneous adverse events of biological therapy for psoriasis: review of the literature. Dermatology, 2005, 211, 209-217.